Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma
Authors:
- Melissa AlsinaMAMelissa Alsina
- Fiona CraigFCFiona Craig
- Toshiyuki YonedaTYToshiyuki Yoneda
- Judith L AndersonJAJudith L Anderson
- Mark DallasMDMark Dallas
- G.DAvid RoodmanGRG.DAvid Roodman
- 1 April 2001
- journal article
- Published by Elsevier in Experimental Hematology
- Vol. 29 (4) , 441-447
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL-6 and MMP-1 by the Tumoral EnvironmentJournal of Bone and Mineral Research, 1999
- Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.Journal of Clinical Oncology, 1998
- Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.Journal of Clinical Oncology, 1998
- Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.Journal of Clinical Investigation, 1997
- Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption.Endocrinology, 1996
- Targeting simian virus 40 T antigen to the osteoclast in transgenic mice causes osteoclast tumors and transformation and apoptosis of osteoclasts.Endocrinology, 1995
- Management of Acute HypercalcemiaNew England Journal of Medicine, 1992
- BM 21.0955, a potent new bisphosphonate to inhibit bone resorptionJournal of Bone and Mineral Research, 1991
- Sequential Expression of Phenotype Markers for Osteoclasts during Differentiation of Precursors for Multinucleated Cells Formed in Long Term Human Marrow Cultures*Endocrinology, 1990
- Identification of Committed Mononuclear Precursors for Osteoclast-Like Cells Formed in Long Term Human Marrow Cultures*Endocrinology, 1990